My site

LONDON - Monday, July 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- EY announced today that Felice Persico has become its Global Vice Chair for Assurance. Felice will lead a business of over 65,000 professionals worldwide, providing services that include: financial statement audit; fraud investigation and dispute services; financial accounting advisory services; and climate change and sustainability services.

Felice was previously the Assurance Leader for EY’s Europe, Middle East, India and Africa (EMEIA) business. He joined EY in 1986 and has served as Assurance COO for EMEIA as well as Assurance Leader for Italy and Continental Western Europe. Felice is the global lead audit Partner for several global Fortune 100 companies and also has extensive experience in assisting companies with capital market transactions, as well as in financial due diligence and valuation services.

Felice says: "The dynamic global business landscape is reshaping the financial and reporting en ... Read more »

New App Connects Single Images to Multiple Interactive Behind the Scenes Content

MIAMI - Sunday, July 21st 2013 [ME NewsWire]

(BUSINESS WIRE) Reel Code Media, a new app, is making a splash during Mercedes-Benz Fashion Week Swim, Miami’s most anticipated fashion event. The innovative app lets attendees view and control multiple types of interactive behind the scenes content after scanning a single framed image.

For users the app is simple to learn. To activate content such as videos, links, promotions and more; users scan any Reel Code Media image, select one of the four corners of the frame and drag it to the center of their viewing screen. For advertisers there's no need to change signage to deliver new updates because the content can be customized at the back end - even after the image using Reel Code technology has been released to the public - allowing promotion and advertising to be updated daily. A major benefit of the app is the ability to serve multiple in ... Read more »

SUMMIT, N.J, - Sunday, July 21st 2013 [ME NewsWire]

(BUSINESS WIRE) Celgene Corporation (NASDAQ: CELG) today announced that after consultation with the U.S. Food and Drug Administration (FDA) Celgene will discontinue treatment with REVLIMID® (lenalidomide) in the open-label, phase III ORIGIN® trial, which enrolled 450 patients in over 100 sites in 26 countries. An imbalance was observed in the number of deaths in patients treated with lenalidomide versus patients treated with chlorambucil.

The FDA placed the ORIGIN study on clinical hold on July 12, 2013, with the discontinuation of lenalidomide treatment. All clinical investigators in ongoing chronic lymphocytic leukemia studies using lenalidomide will be officially advised of this action and instructed to inform their patients accordingly.

REVLIMID is not approved as a treatment for patients with chronic lymphocytic leukemia.

The ORIGIN study was designed to evaluate the efficacy and safety of lena ... Read more »